CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Matthew Gline

Chief Executive Officer & Director, ROIVANT SCIENCES LTD

Search every verified Matthew Gline interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Matthew Gline, CEO of Roivant Sciences, participated in a Post-Hoc Live event in Boston on August 10, 2026, discussing how China's biotech rise is affecting innovation and drug development. During the panel, he argued that certain parts of the drug discovery chain, such as antibody and small molecule discovery, have become commoditized. He also stated that the current US drug pricing system is the primary factor protecting American access to medicines, as it incentivizes global inventors to pursue US clinical trials for financial reasons. Gline also expressed concerns about the US talent pipeline, saying that immigration policies and the declining popularity of academic institutions have weakened the country's ability to maintain its innovative edge. He advocated for reinvesting in the domestic talent base as a key policy priority, while cautioning against protectionism. He noted that while Chinese drugs should not be denied entry to the US market, he emphasized the importance of maintaining a sovereign industrial capacity for medicine production, citing potential geopolitical tensions involving Taiwan.

Recent appearances

  • Live from Boston: Has China changed how we build companies?

    August 10, 2026 · 📺 Endpoints News

    In a world where promising drugs are quickly copied, improved on and raced into trials, is science still a differentiator? Strand Therapeutics CEO Jake Becraft and Roivant Sciences CEO Matt Gline discussed what actually counts as innovation, and if where the innovation happens matters for how the industry brings programs to patients. Be the first to hear about Post-Hoc Live episodes and events, plus behind-the-scenes analysis from the reporters behind them. Sign up for the Post-Hoc newsletter: https://shorturl.at/jtlpf

    Watch on YouTube ↗

  • AI Jitters Return as Markets Await Jobs Data | Open Interest 8/6/2026

    August 06, 2026 · 📺 Bloomberg Television

    Get a jump start on the US trading day with Dani Burger on "Bloomberg Open Interest." Fresh AI weakness keeps investors on edge amid US-Iran talks and ahead of tomorrow's jobs report. Billions worth of SpaceX shares become eligible for trading following the company's post-earnings plunge. And AI investor Leopold Aschenbrenner returns to the investing game with a $400 million bet. Plus: the CEOs of Krispy Kreme, Smashburger, Roivant, and Lincoln International -- covering everything from food to biotech to M&A. Chapters: 00:00:00 - Open Interest 00:01:21 - AI Infrastructure Demand, Memory C…

    Watch on YouTube ↗

  • Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model

    July 09, 2026 · 📺 BioCentury Video

    Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal, which could soon be realized with the approval and launch of brepocitinib this year. In conversation with Lindsay Martin on The BioCentury Show, Gline discussed how Roivant’s initial hub-and-spoke approach has provided the foundation needed for the company to develop and commercialize its portfolio now, including lead program JAK-1/TYK2 inhibitor brepocitinib. Gline also discussed how he vi…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →